FDA Approves VEKLURY — Gilead Sciences, Inc.

The FDA’s approval of Gilead Sciences, Inc.’s intravenous remdesivir (VEKLURY) marks a significant milestone for the company’s antiviral portfolio, potentially cementing the product's commercial dominance for COVID-19 hospitalizations. This regulatory clearance not only validates Gilead’s strategic positioning in the treating of severe respiratory illnesses but also assures investors of continued revenue streams from both branded and generic markets as the industry pivots toward sustained demand.